<![CDATA[Opening Remarks and the Frontline Treatment Landscape in Advanced HCC]]>
Trending
- 42 Intraoperative Frozen Analysis of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy Does Not Provide Additional Surgical Benefit and Increases the Rate of Unnecessary ALND in Clinically Node-Negative Breast Cancer Patients
- 41 Unexpected While Expecting: Rare Case of Pregnancy Associated Xanthogranulomatous Mastitis Masquerading as Malignancy
- Anti-PDGFRα autoantibody – a novel diagnostic and prognostic marker – may mediate non-small cell lung cancer progression via the PI3K/AKT/NF-κB signaling pathway
- Wrapping a “Warm Blanket” Around Patients in a State-of-The-Art Center
- CircZBTB46, a promising therapeutic target in crizotinib resistant ALK-positive T lymphomas
- AI and MRD Take Center Stage on Day 2 of ASCO Breakthrough 2026
- A novel circSLIT2-encoded SLIT2 isoform suppresses neural invasion in gastric cancer
- SUMOylation-stabilized G6PD orchestrates metabolic rewiring for oxidative stress survival and chemoresistance in HCC via a PKCδ-phosphorylation trigger

![<![CDATA[Opening Remarks and the Frontline Treatment Landscape in Advanced HCC]]> Guilherme Perini, MD, PhD, explained the rationale behind the KEYFORM-008 trial, exploring how targeting LAG-3 can reverse checkpoint inhibitor resistance.](https://news.shareyourcancerstories.com/wp-content/uploads/2026/06/ltCDATAReviewing-the-HIMALAYA-Trial-of-Tremelimumab-Plus-Durvalumab-in-Unresectable-768x432.png)